



Project ECHO® (Extension for Community Healthcare Outcomes)
Hepatitis B Initial Case Presentation Form



Presentation Date: 8/22/22 Site: HICHC Clinician: Victoria Fox-Behrle, MD

General Information/Demographics

Patient ECHO ID: HBV_01	Age: 50	Country of Birth: Phillipiiies	Sex at Birth: M	Gender Identity: Male	
Race:	American Indian or Alaska Native <input type="checkbox"/>	Native Hawaiian /Other Pacific Islander (specify): <input checked="" type="checkbox"/>		Ethnicity:	
	Asian (specify): <input type="checkbox"/>	White <input type="checkbox"/>		Hispanic or Latino <input type="checkbox"/>	
	Black or African American <input type="checkbox"/>	Other <input type="checkbox"/>		Not Hispanic or Latino <input checked="" type="checkbox"/>	
Insurance:	None <input type="checkbox"/>	Commercial Health Insurance <input checked="" type="checkbox"/>			
	Medicare <input type="checkbox"/>	Other: <input type="checkbox"/>			
	Medicaid, Quest (if in HI, please specify):				
	AlohaCare <input type="checkbox"/>	HMSA <input type="checkbox"/>	Kaiser <input type="checkbox"/>	Ohana <input type="checkbox"/>	UHC <input type="checkbox"/>

What is the primary question you have regarding this patient:

For this patient:

- 1) Hepatitis B labs were checked in response to transaminitis (not general screening), when do you recommend routine screening?
- 2) Ultrasound was ordered for transaminitis before hepatitis B infection was found. Do you recommend elastography for all evaluation of transaminitis? Or wait to get labs before ordering imaging?
- 3) Treatment recommendations for this patient
- 4) If treatment not recommended, monitoring recommendations

Chronic Hepatitis B Screening

	HBsAg (surface Antigen)	Anti-HBc (core Antibody)	Anti-HBs (surface Antibody)	Interpretation/Management
Patient Results	+ <input type="checkbox"/>	+ <input type="checkbox"/>	-	
	+	+	-/+	Current infection, initial evaluation below; consider treatment
	-	+	+	Prior infection with immune control No transmission risk Reactivation risk if immunosuppressed
	-	+	-	Prior infection or occult infection No transmission risk (<i>unless HBV DNA+</i>) Reactivation risk if immunosuppressed Check HBV DNA for occult infection if immunocompromised
	-	-	+	Immune result from vaccination
	-	-	-	Susceptible -VACCINATE



History and Physical Exam

Height (in): 68	Weight (lbs): 162	BMI: 24.7	
Signs/ symptoms of cirrhosis	Yes <input type="radio"/>	No <input checked="" type="radio"/>	Describe:
Metabolic risk factors (diabetes, dyslipidemia?)	Yes <input type="radio"/>	No <input checked="" type="radio"/>	Describe:

Psychiatric Diagnoses	Depression <input type="checkbox"/>	Anxiety <input type="checkbox"/>	Other: <input type="checkbox"/>
Depression Screening:	PHQ 9: N/A	PHQ 2: 0	Other:

Substance Use History	Does the person have a substance use disorder?		Yes <input type="radio"/>	No <input checked="" type="radio"/>
	If yes, Alcohol <input type="checkbox"/>	Opiates <input type="checkbox"/>	Stimulants <input type="checkbox"/>	
	Benzodiazepines <input type="checkbox"/>	Marijuana <input type="checkbox"/>	Other: <input type="checkbox"/>	
	If yes, date of last use (for each): No AUD but drinks 1-2 drinks 2-3x per			
	History of injecting drugs?	Yes <input type="radio"/>	No <input checked="" type="radio"/>	If yes, date of last injection:

Family history of HCC, CHB, or cirrhosis	Yes <input checked="" type="radio"/>	No <input type="radio"/>
Relationship Brother	Age at diagnosis or death Unknown, uncomplicated chronic Hep B infection per patient	
Relationship	Age at diagnosis or death	

Household and sexual contact screening:	Done <input type="radio"/>	Not done <input checked="" type="radio"/>
---	----------------------------	---

Hepatitis A vaccination status:	Vaccinated <input type="radio"/>	Not vaccinated or uncertain <input checked="" type="radio"/>
---------------------------------	----------------------------------	--

Pregnant:	No <input checked="" type="radio"/>	Yes <input type="radio"/>	Due Date:
-----------	-------------------------------------	---------------------------	-----------

Routine Labs	Date	Date	Date	Date	Date
	3.59 millid	7/26/21	11/19/21		
CBC: Platelet Count	234				
CMP: AST	54	60	36		
ALT	74	84	42		
Total Bilirubin	0.5	0.6	0.4		
Alkaline Phosphatase	65	68	57		
Albumin	4.6	4.7	4.7		
Creatinine	0.83				
INR	not done				
Other					



Project ECHO® (Extension for Community Healthcare Outcomes)
Hepatitis B Initial Case Presentation Form



Hepatitis-related Labs

Date Date Date Date Date
3.59 milliu 7/26/21 11/19/21
HBV DNA 3.59 milliu 7/26/21 11/19/21 (if >2000 IU/ml AND elevated ALT: consider treatment)

Table with 2 columns for test results: Positive and Negative. Rows include HBeAg, HBeAb, Anti-HAV, Anti-HCV, HIV Ab, Anti-HDV, APRI Score, and Fib-4 Score.

Imaging/ Staging

Table for imaging/staging with columns: Modality (Elastography, CT, MRI, U/S), Date, Findings. Includes text: 'Liver measure 11cm cranial-caudal. Echotexture is norr'

Current Medications (including herbal or supplements):

Two tables for medication tracking with columns: Medication Name, Dosage, Frequency.

Anti-viral therapy? Name: Date started:

Please list any additional pertinent information about the patient:

HBV genotype: A
Mutation testing:
Polymerase mutations:
3TC - A181T/A, M204m/v
LDT - none
ADV - A181T/A
ETV - none

PLEASE NOTE that case consultations do not create or otherwise establish a provider-patient relationship between any clinician and any patient whose case is being presented in this clinical setting.

Pt age: 50 gender: male wt: 162 lbs ht: 68 in PT ID#: HBV_01

Race: Asian Birthplace: Phillipines, came to Hawai'i in 1990's

Family history of HBV and HCC: Brother with HBV, denies family hx of HCC

Test Name	Date of assessment	Result
HBsAg (surface antigen)	7/26/2021	Reactive
HBsAb	7/26/2021	Non-reactive
HBcAb total	7/26/2021	Reactive
HBeAg (e antigen)	11/19/2021	Positive
Anti-HBc IgM	11/19/2021	Non-reactive
Anti-HBc IgG	11/19/2021	Not assessed
Anti-HBeAg (e antibody)	11/19/2021	Negative
HBV DNA		3.59 million (Log 6.555)
HBV Genotype	11/19/2021	A
Mutation Testing	11/19/2021	Polymerase mutations: <ul style="list-style-type: none"> • 3TC – A181T/A, M204m/v • LDT – none • ADV – A181T/A • ETV – none • Other: S202N/S Precore Mutations: NOT DETECTED BCP Mutations: A1762T, G1764A
HCV Antibody	7/15/2021	Non-reactive
Anti-HIV	7/15/2021	Non-reactive
Anti-HAV (total or IgG)	11/19/2021	Immune (reactive)
Anti-HDV		Not assessed
CBC (within 12 weeks)	7/15/2021	Platelets = 234 K
Liver function panel	11/19/2021	AST = 36 IU/L ALT = 42 IU/L Alk Phos = 57 IU/L Total bili = 0.4 mg/dL Direct bili = <0.2 mg/dL Albumin = 4.7 g/dL
INR (within 12 weeks)		Not assessed
eGFR/BUN/Cr/Bili	7/15/2021	eGFR = 103 mL/min BUN = 9 mg/dL SCr = 0.83 mg/dL
AFP		Not assessed
Signs/Symptoms of cirrhosis		None - VFB
Substance use history		1-2 alcoholic beverages "few times per week"
FIB-4 Score		1.19 advanced fibrosis excluded
APRI Score		0.4 unable to determine severity
Child Pugh Score		Unable to calculate without INR
Fibrosis Score		Not assessed

Imaging	7/30/2021	Liver measure 11cm cranial-caudal. Echotexture is normal. Normal external hepatic contour. No hepatic mass. Normal directional flow hepatic and portal veins. Spleen not well-visualized due to body habitus.
Drug-Drug Interaction screening		Not applicable at this time

Patient is **treatment naïve or experienced**

Previous treatment (drug/dates): none

Treatment Plan:

Hepatitis A vaccine: not indicated, patient is immune

Medication:

Follow-up: